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cervical lymph nodes and multiple solid nodules within the pelvis. The
patient was re-treated with carboplatin–paclitaxel with a complete re-
sponse, but her disease recurred 6-months later with supraclavicular,
mediastinal, axillary, and retroperitoneal lymphadenopathy, a pleural ef-
fusion, and peritoneal nodularity, identiﬁed by CT imaging. The patient
then began treatmentwith, but progressed through several regimens, in-
cluding pegylated liposomal doxorubicin, weekly paclitaxel, topotecan,
and a clinical trial regimen (docetaxel and an anti-vascular endothelial
growth factor molecule). During the course of treatment for recurrentIntroduction
Breast metastases from ovarian carcinoma (OC) have scarcely been
reported. Morphologic and radiographic similarities between primary
breast cancers (BC), and high grade papillary serous (PS) OC make
distinguishing between the two diagnoses challenging, yet carry impor-
tant consequences for treatment and prognosis. Herein, we describe a
patient with a metastatic OC presenting with a palpable breast mass
and discuss the utility of immunohistochemistry for distinguishing be-
tween OC and BC.
Case
A 52-year-old woman with no familial cancer history and an un-
known BRCA-status presented with a palpable right breast mass. Four
years earlier, she had been diagnosed with and treated for advanced
stage high grade PS OC with neoadjuvant carboplatin–paclitaxel
followed by an optimal interval cytoreductive surgery and additional
chemotherapy. Her serum cancer antigen-125 (CA-125) normalized
after treatment, and she had no evidence of disease. At the time of her
ﬁrst recurrence, 16-months later, her serum CA125 was 453U/mL and a
biopsy of a xyphoid mass revealed recurrent high grade PS OC. A chest,ology, Department of Obstetrics
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-ND license.ovarian cancer, a breast exam revealed a 5 cm ﬁxed right breast mass
at the 9-o'clock position and right axillary lymphadenopathy. Amammo-
gram showed a 5×1.8×1.6 cm heterogeneous density with calciﬁca-
tions (BIRADS Category 4). The patient had no prior mammograms for
comparison. Four ultrasound-guided core biopsies from the breast
were evaluated by hematoxylin and eosin (H&E). Microscopically, the
normal parenchyma was completely replaced by solid tumor with mul-
tiple areas showing a papillary pattern. Tumor cells exhibited moderate
pleomorphism, prominent nucleoli, high nuclear-cytoplasmic ratio, and
numerous mitoses (Fig. 1a, b).
Here, the main differential diagnoses were primary invasive
micropapillary carcinoma (IMPC) of the breast versus metastatic
PS OC. Immunohistochemical analyses of tumor cells for Paired-box-
gene-8 (PAX8), Wilms' tumor-1 (WT1), cytokeratin (CK)7, CK20,
CA125, gross cystic disease protein ﬂuid (GCDPF-15)/BRST2, mamma-
globin, Estrogen Receptor (ER), and Progesterone Receptor (PR) were
positive for PAX8, WT1, CK7 and CA125, and negative for CK20, ER/PR,
BRST2 and mammaglobin (Fig. 1c, d), thereby establishing a diagnosis
of metastatic PS OC. After appropriate counseling regarding her overall
clinical picture, the patient opted for best supportive care and passed
away 3 months later.Discussion
Secondary tumors to the breast are rare, accounting for approxi-
mately 2% of all malignant mammary tumors. The majority of metasta-
ses are from the contralateral breast, and the most common extra-
mammary sites include lymphomas, melanomas, and those from the
gastrointestinal tract (Georgiannos et al., 2001). Breast metastasis
from primary OC is uncommon. Common modes of OC dissemination
are via intraperitoneal implantation and lymphatic and hematogenous
Fig. 1. a and b: The breast tissue was occupied by proliferation of neoplastic cells. The cells had a diffuse inﬁltrative pattern. However in areas the tumor exhibited a micropapillary
pattern. (H&E ×20). (Insert) The tumor cells were moderately pleomorphic with high nuclear/cytoplasmic ratio and prominent nucleoli. Immunohistochemistry showed tumor
cells to be diffusely and strongly positive for WT (c) and for PAX8 (d). Both expressions were in a nuclear pattern.
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sites of distant OC metastasis, but factors favoring metastases to the
breast include the absence of hereditary breast–ovarian cancer, a histo-
ry of recurrent/advanced OC, and a shorter interval between OC diagno-
sis and development of breastmass (Georgiannos et al., 2001; Cormio et
al., 2003).
Because the majority of metastatic OC are high grade PS,
distinguishing them from breast IMPC is challenging. Mammo-
graphically, both lesions appear as heterogeneous masses with micro-
calciﬁcations. Microscopically, both have marked nuclear atypia, brisk
mitotic activity and papillary architectural patterns. The co-existence
of ductal-carcinoma-in-situ (DCIS) favors primary BC; however, DCIS
may be absent in biopsies due to sampling variability. Therefore, immu-
nohistochemistry is an essential diagnostic adjunct.
OC and BC share many immunohistochemical proﬁles (e.g., ER,
PR, HER2/neu, CA125, CK7, CK20) (Tornos and Solslow, 2005;
Nonaka et al., 2008). Other candidate markers (e.g., GCDPF-15/
BRST2, WT1, PAX8, PAX2, and mammaglobin) are also being consid-
ered (Ozcan et al., 2011; McKnight et al., 2010). GCDPF-15/BRST2
and mammaglobin have low sensitivity for BC, thereby limiting its
diagnostic utility (Tornos and Solslow, 2005; Nonaka et al., 2008).
WT1 and PAX8 appear to have the greatest utility in differentiating
primary BC from metastatic OC due to their high sensitivity and
low potential for aberrant expression. WT1 is detected in 94.7% of
serous OC, 100% peritoneal serous carcinomas, and 2–3% IMPC,
thereby limiting its utility here (Tornos and Solslow, 2005). PAX8,
a transcription factor expressed in tumors of renal, mullerian and
thyroid origin, is present in 99% of serous OC and absent in all BC in-
cluding IMPC (Nonaka et al., 2008; Lotan et al., 2009). Thus, a posi-
tive PAX8 result here readily excludes primary BC. Although PAX2
is also a transcription factor essential in embryonic developmentof mullerian organs, PAX8 appears to be a superior epithelial marker
for distinguishing metastatic mullerian epithelial tumors from nor-
mal and non-neoplastic tumors (Ozcan et al., 2011).
Distinguishing metastatic OC from primary BC has important
prognostic and therapeutic implications. Because breast metastases
commonly present in the setting of advanced-stage disease, overall
survival is poor. Therapeutically, localized primary IMPC is managed
mainly by surgical excision followed by chemoradiation, whereas
metastatic OC to the breast here would represent recurrent OC and
typically be treated with chemotherapy.
Summary
Although relatively uncommon, metastatic tumors to the breast
should be appreciated so that a secondary malignancy from rare
sites (e.g., ovary), is not overlooked. Accurate diagnosis of these
metastases is important because the prognosis and therapies differ
dramatically. While the clinical history and morphology can help
distinguish between primary and metastatic BC, immunohisto-
chemistry is essential when the diagnosis is still vague. PAX8
seems to be important in differentiating OC from BC. We recom-
mend evaluating PAX8 immunohistochemistry when metastatic
OC is suspected.
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